178 related articles for article (PubMed ID: 36186460)
1. Economic evaluation of using polygenic risk score to guide risk screening and interventions for the prevention of type 2 diabetes in individuals with high overall baseline risk.
Martikainen J; Lehtimäki AV; Jalkanen K; Lavikainen P; Paajanen T; Marjonen H; Kristiansson K; Lindström J; Perola M
Front Genet; 2022; 13():880799. PubMed ID: 36186460
[TBL] [Abstract][Full Text] [Related]
2. Economic Evaluation of a New Polygenic Risk Score to Predict Nephropathy in Adult Patients With Type 2 Diabetes.
Guinan K; Beauchemin C; Tremblay J; Chalmers J; Woodward M; Tahir MR; Hamet P; Lachaine J
Can J Diabetes; 2021 Mar; 45(2):129-136. PubMed ID: 33032912
[TBL] [Abstract][Full Text] [Related]
3. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
4. Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis.
Jalkanen K; Aarnio E; Lavikainen P; Lindström J; Peltonen M; Laatikainen T; Martikainen J
BMC Health Serv Res; 2021 Sep; 21(1):916. PubMed ID: 34482831
[TBL] [Abstract][Full Text] [Related]
5. Estimating the cost-effectiveness of lifestyle intervention programmes to prevent diabetes based on an example from Germany: Markov modelling.
Neumann A; Schwarz P; Lindholm L
Cost Eff Resour Alloc; 2011 Nov; 9(1):17. PubMed ID: 22099547
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
10. Benefits and harms of polygenic risk scores in organised cancer screening programmes: a cost-effectiveness analysis.
Xia C; Xu Y; Li H; He S; Chen W
Lancet Reg Health West Pac; 2024 Mar; 44():101012. PubMed ID: 38304718
[TBL] [Abstract][Full Text] [Related]
11. Polygenic Risk Score, Lifestyles, and Type 2 Diabetes Risk: A Prospective Chinese Cohort Study.
Liu J; Wang L; Cui X; Shen Q; Wu D; Yang M; Dong Y; Liu Y; Chen H; Yang Z; Liu Y; Zhu M; Ma H; Jin G; Qian Y
Nutrients; 2023 Apr; 15(9):. PubMed ID: 37432247
[TBL] [Abstract][Full Text] [Related]
12. Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk-Enhancing Factor in the Pooled Cohort Equation: A Cost-Effectiveness Analysis Study.
Mujwara D; Henno G; Vernon ST; Peng S; Di Domenico P; Schroeder B; Busby GB; Figtree GA; Bottà G
J Am Heart Assoc; 2022 Jun; 11(12):e025236. PubMed ID: 35699184
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
14. Integrating polygenic risk scores in the prediction of type 2 diabetes risk and subtypes in British Pakistanis and Bangladeshis: A population-based cohort study.
Hodgson S; Huang QQ; Sallah N; ; Griffiths CJ; Newman WG; Trembath RC; Wright J; Lumbers RT; Kuchenbaecker K; van Heel DA; Mathur R; Martin HC; Finer S
PLoS Med; 2022 May; 19(5):e1003981. PubMed ID: 35587468
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening.
Mital S; Nguyen HV
BMC Cancer; 2022 May; 22(1):501. PubMed ID: 35524200
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?
Siegel KR; Ali MK; Zhou X; Ng BP; Jawanda S; Proia K; Zhang X; Gregg EW; Albright AL; Zhang P
Diabetes Care; 2020 Jul; 43(7):1557-1592. PubMed ID: 33534729
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
